Orelabrutinib is a drug for the treatment of cancer.

In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]

Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.[2]

References

  1. ^ Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
  2. ^ Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605. PMID 37078706.


Allikas: Https://en.wikipedia.org/wiki/Orelabrutinib
No tags for this post.